Home/Pipeline/Oncology Programs

Oncology Programs

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Kymera Therapeutics

About Kymera Therapeutics

Kymera Therapeutics is advancing a robust pipeline of PROTAC degraders targeting transcription factors, scaffolding proteins, and other previously undruggable proteins across oncology, immunology, and other therapeutic areas. The company has built a proprietary platform combining computational chemistry, structural biology, and proteomics to design selective protein degraders. With multiple programs in clinical development and strategic partnerships with leading pharmaceutical companies, Kymera is positioned as a leader in the emerging protein degradation field.

View full company profile

Therapeutic Areas

Oncology Immunology Rare Diseases

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active